Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
20 hedge funds and large institutions have $352K invested in Baudax Bio, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
5% more funds holding
Funds holding: 19 → 20 (+1)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
67% less capital invested
Capital invested by funds: $1.08M → $352K (-$727K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$228K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$137K |
| 3 |
VF
Virtu Financial
New York
|
+$51.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$40.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$28.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$389K |
| 2 |
Walleye Capital
New York
|
-$165K |
| 3 |
Renaissance Technologies
New York
|
-$45.9K |
| 4 |
HF
HRT Financial
New York
|
-$19K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3K |
BXRX Hedge Fund Activity: Q3 2022 in Review
20 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q3 2022, worth a combined $352K — down 67% from $1.08M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BXRX positions and 5 closed out — a net gain of 1 holder — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Sabby Management, adding an estimated $228K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $389K sold.
- 20 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q3 2022, up from 19 in Q2 2022.
- Funds reported $352K of Baudax Bio, Inc. Common Stock stock for Q3 2022, down 67% quarter-over-quarter.
- 6 funds opened new Baudax Bio, Inc. Common Stock positions in Q3 2022 and 5 closed out, a net change of +1 holder.
- The largest Baudax Bio, Inc. Common Stock buyer in Q3 2022 was Sabby Management, an estimated $228K added.
- The largest Baudax Bio, Inc. Common Stock seller in Q3 2022 was Alyeska Investment Group, an estimated $389K sold.
Based on aggregated 13F filings for Q3 2022.